Please ensure Javascript is enabled for purposes of website accessibility
David Liang

David Liang


Recent articles

money and pills on scale

AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know

Could the world's best-selling drug have a protégé?

money and pills on scale

Amicus Therapeutics: Is This Biotech an Orphan Underdog?

After months of crazy volatility, the stock seems to have made up its mind on which direction to go: up

hand drawing chart stock return

Celgene's Next Blockbuster: What You Need to Know

Could Celgene's newest drug finally get this company the respect it deserves?

hand drawing chart stock return

Omeros: Can the Growth Story Continue?

After a 60% increase since the start of 2017, can shares continue to move higher?

jenga tower risk

Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?

Does Zogenix stand a chance against the cannabis king?

money and pills on scale

With Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory?

Shares of Synergy are down, but things are looking up for this GI gem

money and pills on scale

Two Red Hot Biotechs With Big Near-term Catalysts Ahead

June will be a pivotal month for shareholders of Portola Pharmaceuticals and Neos Therapeutics

money and pills on scale

Could This Tiny Biotech Be the David to Mylan's EpiPen Goliath?

Adamis is working on an EpiPen alternative, and the payoff could be huge

jenga tower risk

Biogen and Alzheimer’s: There’s a Fundamental Problem Here

Biogen's "moonshot" will likely end in failure

money and pills on scale

Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market

After a significant pullback in April, is now the right time to jump into Acadia?


Axovant: A New CEO Doesn't Change Anything

A hedge fund founder and a once-failed drug are a recipe for disaster

money and pills on scale

Why Shares of Portola Pharmaceuticals Are Up Over 60% in 2017

A combination one-two punch has left investors cheering


Amgen's Offering a Money Back Guarantee for Repatha. Will It Be Enough?

After a slow start, are sales of Repatha finally about to pick up?


Sanofi Buying Flexion: A Smart Move?

Will Sanofi acquire anything? Or is this deal smarter than it seems?

debt past due notice

Bill Ackman Just Gave Up on Valeant. Should You Too?

What lessons should investors learn from Ackman's greatest mistake?

hand drawing chart stock return

Aurinia Pharmaceuticals: Where to From Here?

After dropping more than 30% off its highs, is now the time to buy this baby biotech?

jenga tower risk

Battle in the Boardroom: What's Next for Immunomedics

Will VenBio successfully negotiate a higher bid for IMMU-132?

jenga tower risk

Why Shares of Immunomedics Inc Are up an Astounding 89% in 2017

Will shares move higher? Or will a boardroom battle leave this biotech cruising for a bruising?

man holding money hundred bills

After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?

Beneath the surface, Rigel has been gearing up for an explosive 2017

hand drawing chart stock return

Omeros: Power in the Pipeline

This tiny biotech could be Alexion's worst nightmare

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.